查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1544760

血友病治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Hemophilia Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 390 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于对血友病的认识和诊断不断提高，加上医学研究和技术的进步，全球血友病治疗市场在 2024 年至 2032 年间将呈现 5.6% 的复合年增长率。改良的诊断技术可以更早、更准确地识别血友病，从而可以及时进行干预和治疗。

此外，製药公司对研发的投资不断增加，正在促进治疗方案的创新，推动市场扩张。举个例子，2024 年 5 月，赛诺菲、Formation Bio 和 OpenAI 宣布建立突破性合作伙伴关係，共同开发人工智慧驱动的软体，以加快药物开发速度。此次合作将整合资料、软体和客製化模型，标誌着製药和生命科学领域的首次合作。医疗基础设施的增强和医疗支出的增加正在促进血友病治疗行业的成长。

整个市场根据疾病类型、产品、患者、药物类别、治疗、给药途径、治疗、最终用途和地区进行分类。

由于意识的提高和诊断能力的提高，B 型血友病细分市场在预测期内将经历显着扩张。此外，对个人化医疗和标靶治疗的日益关注推动了专门针对 B 型血友病患者的治疗方案的进步。对血友病研究的更多支持和专门治疗方案的开发进一步增强了对该领域的关注。

到 2032 年，延长半衰期产品领域将在血友病治疗市场占据显着份额，因为它们能够减少有效疾病管理所需的输注频率。这意味着提高患者的便利性和对治疗方案的依从性。半衰期延长的产品还具有增强的稳定性和功效，从而更好地全面管理血友病。患者和医疗保健提供者的偏好正在增加对血友病治疗的延长半衰期产品的需求。

从2024年到2032年，由于更好的医疗基础设施和先进医疗技术的普及，欧洲血友病治疗产业将呈现令人印象深刻的成长趋势。在大量政府和私人投资的支持下，对研究和发展的高度重视正在促进治疗方案的创新。此外，对血友病认识的提高和早期诊断导致对有效治疗的更高需求。有利的医疗报销政策的存在正在塑造欧洲的市场前景。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 全球血友病患病率不断上升
      • 有利的政府措施增加
      • 加大研发力道及新产品开发
      • 越来越多采用预防治疗
    • 产业陷阱与挑战
      • 血友病治疗相关的高费用
      • 发展中和欠发达地区缺乏认识
      • 技术先进产品的采用率低
  • 成长潜力分析
  • 监管环境
  • 未来市场趋势
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按疾病类型，2021 - 2032

  • 主要趋势
  • 甲型血友病
    • 剧烈
    • 缓和
    • 轻微
  • 乙型血友病
    • 剧烈
    • 缓和
    • 轻微
  • 其他疾病类型

第 6 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 重组凝血因子浓缩物
    • 因子VIII
    • 因子IX
  • 血浆源性凝血因子浓缩物
    • 因子VIII
    • 因子IX
  • 延长半衰期的产品
    • 因子VIII
    • 因子IX
  • 去氨加压素
  • 抗纤维蛋白溶解剂
  • 基因治疗产品

第 7 章：市场估计与预测：按患者分类，2021 - 2032 年

  • 主要趋势
  • 儿科
    • 0 到 4
    • 5 至 13
    • 14 至 18
  • 成人
    • 19 至 44
    • 45+

第 8 章：市场估计与预测：按处理方式，2021 - 2032

  • 主要趋势
  • 预防
  • 一经请求

第 9 章：市场估计与预测：按治疗方式，2021 - 2032 年

  • 主要趋势
  • 因子替代疗法
  • 非因子替代疗法

第 10 章：市场估计与预测：按药物类别，2021 - 2032 年

  • 主要趋势
  • 加压素
  • 凝血因子

第 11 章：市场估计与预测：按管理途径，2021 - 2032 年

  • 主要趋势
  • 可注射
  • 鼻喷剂
  • 口服

第 12 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 诊所
  • 血友病治疗中心
  • 其他最终用户

第 13 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 14 章：公司简介

  • Bayer AG
  • Biogen Inc.
  • Biotest AG (Grifols, S.A.)
  • BioMarin Pharmaceutical Inc
  • CSL Behring LLC
  • Ferring B.V.
  • Genentech, Inc. (Roche Holding AG)
  • Kedrion S.p.A
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer, Inc.
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
简介目录
Product Code: 2772

Global Hemophilia Treatment Market will exhibit a 5.6% CAGR between 2024 and 2032, driven by the increasing awareness and diagnosis of hemophilia, coupled with advancements in medical research and technology. The improved diagnostic techniques have led to early and more accurate identification of hemophilia, allowing for timely intervention and treatment.

Additionally, growing investment in research and development by pharmaceutical companies is fostering innovation in treatment options, propelling market expansion. Citing an instance, in May 2024, Sanofi, Formation Bio, and OpenAI announced a groundbreaking partnership to develop AI-driven software for faster drug development. This collaboration will integrate data, software, and custom models, marking a first-of-its-kind effort in pharma and life sciences. Enhanced healthcare infrastructure and increasing medical expenditure are contributing to the growth of the hemophilia treatment industry.

The overall market is categorized based on disease type, product, patient, drug class, treatment, route of administration, therapy, end-use, and region.

The hemophilia B segment will experience prominent expansion during the forecast period, attributed to heightened awareness and improved diagnostic capabilities. Additionally, the growing focus on personalized medicine and targeted therapies has driven advancements in treatment options specifically tailored for hemophilia B patients. Increased support for hemophilia research and the development of specialized treatment protocols are further amplifying the focus on this segment.

By 2032, the extended half-life products segment will achieve a prominent hemophilia treatment market share, owing to their ability to reduce the frequency of infusion required for effective disease management. This translates to improved patient convenience and adherence to treatment regimens. The extended half-life products also offer enhanced stability and efficacy, resulting in better overall management of hemophilia. The preference among patients and healthcare providers is boosting the demand for extended half-life products for hemophilia treatment.

From 2024 to 2032, the Europe hemophilia treatment industry will display an impressive growth graph, owing to the better healthcare infrastructure and access to advanced medical technologies. The strong focus on research and development, supported by substantial government and private investments, is fostering innovation in treatment options. Additionally, increasing awareness and early diagnosis of hemophilia are leading to a higher demand for effective treatments. The presence of favorable medical reimbursement policies is shaping the market outlook in Europe.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing prevalence of hemophilia across the globe
      • 3.2.1.2 Rise in favorable government initiatives
      • 3.2.1.3 Increase in R and D and new product development
      • 3.2.1.4 Growing adoption of prophylaxis treatment
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost associated with hemophilia treatment
      • 3.2.2.2 Lack of awareness in developing and under-developed regions
      • 3.2.2.3 Low adoption rates of technologically advanced products
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Future market trends
  • 3.6 Pipeline analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Hemophilia A
    • 5.2.1 Severe
    • 5.2.2 Moderate
    • 5.2.3 Mild
  • 5.3 Hemophilia B
    • 5.3.1 Severe
    • 5.3.2 Moderate
    • 5.3.3 Mild
  • 5.4 Other disease types

Chapter 6 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Recombinant coagulation factor concentrates
    • 6.2.1 Factor VIII
    • 6.2.2 Factor IX
  • 6.3 Plasma-derived coagulation factor concentrates
    • 6.3.1 Factor VIII
    • 6.3.2 Factor IX
  • 6.4 Extended half-life products
    • 6.4.1 Factor VIII
    • 6.4.2 Factor IX
  • 6.5 Desmopressin
  • 6.6 Antifibrinolytic agents
  • 6.7 Gene therapy products

Chapter 7 Market Estimates and Forecast, By Patient, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Pediatric
    • 7.2.1. 0 to 4
    • 7.2.2. 5 to 13
    • 7.2.3. 14 to 18
  • 7.3 Adult
    • 7.3.1. 19 to 44
    • 7.3.2. 45+

Chapter 8 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Prophylaxis
  • 8.3 On demand

Chapter 9 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Factor replacement therapy
  • 9.3 Non-factor replacement therapy

Chapter 10 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 Vasopressin
  • 10.3 Coagulation factors

Chapter 11 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 11.1 Key trends
  • 11.2 Injectable
  • 11.3 Nasal spray
  • 11.4 Oral

Chapter 12 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 12.1 Key trends
  • 12.2 Hospitals
  • 12.3 Clinics
  • 12.4 Hemophilia treatment centers
  • 12.5 Other end-users

Chapter 13 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 13.1 Key trends
  • 13.2 North America
    • 13.2.1 U.S.
    • 13.2.2 Canada
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 UK
    • 13.3.3 France
    • 13.3.4 Spain
    • 13.3.5 Italy
    • 13.3.6 Netherlands
    • 13.3.7 Rest of Europe
  • 13.4 Asia Pacific
    • 13.4.1 China
    • 13.4.2 Japan
    • 13.4.3 India
    • 13.4.4 Australia
    • 13.4.5 South Korea
    • 13.4.6 Rest of Asia Pacific
  • 13.5 Latin America
    • 13.5.1 Brazil
    • 13.5.2 Mexico
    • 13.5.3 Rest of Latin America
  • 13.6 Middle East and Africa
    • 13.6.1 South Africa
    • 13.6.2 Saudi Arabia
    • 13.6.3 UAE
    • 13.6.4 Rest of Middle East and Africa

Chapter 14 Company Profiles

  • 14.1 Bayer AG
  • 14.2 Biogen Inc.
  • 14.3 Biotest AG (Grifols, S.A.)
  • 14.4 BioMarin Pharmaceutical Inc
  • 14.5 CSL Behring LLC
  • 14.6 Ferring B.V.
  • 14.7 Genentech, Inc. (Roche Holding AG)
  • 14.8 Kedrion S.p.A
  • 14.9 Novo Nordisk A/S
  • 14.10 Octapharma AG
  • 14.11 Pfizer, Inc.
  • 14.12 Sanofi SA
  • 14.13 Swedish Orphan Biovitrum AB
  • 14.14 Takeda Pharmaceutical Company Limited